Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Avacta Systems Dramatically Save Time on Formulation Studies in Korea

Published: Friday, May 10, 2013
Last Updated: Friday, May 10, 2013
Bookmark and Share
Optim 1000 microvolume protein analysis and characterization instrument from Avacta.

Scientists at the specialized biotech company PharmAbcine are completing formulation and stability studies in a fraction of the time thanks to an Optim 1000 microvolume protein analysis and characterization instrument from Avacta Analytical.

PharmAbcine was established in the Republic of Korea in 2008 specifically for the development of human monoclonal antibodies into drugs for the treatment of human diseases, including cancer and inflammatory diseases.

With one product already undergoing clinical trials for blocking angiogenesis in glioblastomas, and a second monoclonal in development stages, the Company is keen to use high throughput technologies where possible, as Dr Weon Sup Lee, Head of the R&D Center at PharmAbcine, explained.

“High throughput is very important in the development of drug formulations, especially for a small company like PharmAbcine. With the Optim 1000 we can simultaneously check conformational change and the aggregation status of our molecule. We now use it routinely for looking at formulation and stability, and for developing purification processes taking many different combinations of factors - pH, buffers, adjuvants - into account. The Optim 1000 is easy to use and requires small sample volumes, which is a real advantage. Unlike techniques such as dynamic light scattering, the samples do not need any pre treatment in order to get good results, so we save time and costs there too.”

Dr Lee concluded: “For our first product we used spectrophotometers and HPLC for the preformulation studies and it took several months. In contrast, the same process for our second molecule was completed within a week using the Optim 1000 with DOE (Design of Experiment). It is simply very fast and reliable.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos